The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Biomarker studies in a phase I trial of DKN-01 in advanced esophageal cancer.
 
John H. Strickler
Consulting or Advisory Role - Amgen; Bayer; Boehringer Ingelheim; Celgene; Genentech/Roche; Onyx
Research Funding - Abbvie (Inst); Bayer (Inst); Exelixis (Inst); Gilead Sciences (Inst); MedImmune (Inst); OncoMed (Inst); Regeneron (Inst); Roche/Genentech (Inst); Sanofi (Inst)
 
Michael Kagey
Employment - Leap Therapeutics; Tensha Therapeutics
Stock and Other Ownership Interests - Leap Therapeutics; Tensha Therapeutics
Patents, Royalties, Other Intellectual Property - Leap Therapeutic, Inc.; Syros Pharmaceuticals; Tensha Therapeutics
 
Cynthia A. Sirard
Employment - HealthCare Pharmaceuticals; Leap Therapeutics
Stock and Other Ownership Interests - HealthCare Pharmaceuticals; Leap Therapeutics
Patents, Royalties, Other Intellectual Property - Leap Therapeutics
 
Gabriel Dan Duda
Consulting or Advisory Role - Hexal
Research Funding - HealthCare Pharmaceuticals (Inst); Merrimack (Inst)
 
Jorge Almenara
No Relationships to Disclose
 
Celeste N. Powers
No Relationships to Disclose
 
Johanna C. Bendell
Research Funding - Apexigen (Inst); Array BioPharma (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Daiichi Sankyo (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Kolltan Pharmaceuticals (Inst); Leap Therapeutics (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Oncogenex (Inst); OncoMed (Inst); SynDevRx (Inst); Taiho Pharmaceutical (Inst)